Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Revenue of Allena Pharmaceuticals, Inc. (ALNAQ)
Revenue in 2021 (TTM): $
According to Allena Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Allena Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2021 | $ | $ | $-31,972,000 | $-32,845,000 | $-33,355,000 |
| 2020 | $ | $ | $-32,679,000 | $-32,845,000 | $-32,845,000 |
| 2019 | $ | $ | $-47,176,000 | $-47,339,000 | $-47,339,000 |
| 2018 | $ | $ | $-35,570,000 | $-35,648,000 | $-35,648,000 |
| 2017 | $ | $ | $-21,577,000 | $-21,650,000 | $-21,650,000 |
| 2016 | $ | $ | $-24,461,000 | $-24,507,000 | $-24,507,000 |
| 2015 | $ | $ | $-14,149,000 | $-14,247,000 | $-14,247,000 |